<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A6EB860C-492A-4661-8DEF-B9177677FBEB"><gtr:id>A6EB860C-492A-4661-8DEF-B9177677FBEB</gtr:id><gtr:name>Faculty of Health and Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Human Genetics</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A6EB860C-492A-4661-8DEF-B9177677FBEB"><gtr:id>A6EB860C-492A-4661-8DEF-B9177677FBEB</gtr:id><gtr:name>Faculty of Health and Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0D664919-39C4-4638-AB75-E82A428AB7F8"><gtr:id>0D664919-39C4-4638-AB75-E82A428AB7F8</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Pearce</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/135BF251-9D97-4560-9F39-9C989A5E1A37"><gtr:id>135BF251-9D97-4560-9F39-9C989A5E1A37</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:otherNames>Louise</gtr:otherNames><gtr:surname>Mitchell</gtr:surname><gtr:orcidId>0000-0002-9946-183X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0900001"><gtr:id>04D0734A-20F7-4F07-A70E-FED7EF82CC30</gtr:id><gtr:title>Revival of autochthonous adrenocortical stem cells in autoimmune Addison's disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900001</gtr:grantReference><gtr:abstractText>The cortex of the adrenal gland manufactures two steroid hormones, cortisol and aldosterone, that are essential for life. The activity of the adrenal cortex, including cortisol and aldosterone production, is controlled by a master regulatory hormone known as ACTH (adrenocorticotrophic hormone). Too much ACTH causes the adrenal glands to expand and to make too much cortisol. In contrast, too little ACTH causes the adrenals to shrink, and results in serious illness owing to steroid deficiency. All the cells of the adrenal cortex start life by dividing from their parent stem cells which are located around the outer edge of the adrenal gland. The proliferation and growth of these parent stem cells is also strongly regulated by the same hormone, ACTH. 


Untreated, autoimmune Addison?s disease is an invariably fatal condition. The adrenal cortex becomes destroyed by an immune system attack, leading to deficiency of the vital steroid hormones, cortisol and aldosterone. During the development of Addison?s disease, the body senses the steroid hormone deficiency, so blood ACTH levels become very high (typically 20-times higher than normal). This is an attempt by the body to stimulate the adrenal cells to divide and make more of the essential steroid hormones. However, once diagnosed and treated with replacement steroid tablets, the ACTH levels fall. Critically, this leads to a worsening of the function of any remaining adrenal stem cells and further reduction in functioning adrenal tissue. The idea of the current project is to give back ACTH to people with treated autoimmune Addison?s disease in order to stimulate the stem cells in their adrenal glands back into activity. The treatment with ACTH would initially be by daily injection for 10 weeks. This could ultimately lead to recovery of adrenal gland function and people with Addison?s disease may then be able to stop their steroid medications. Their condition could be cured.</gtr:abstractText><gtr:technicalSummary>Adrenocortical tissue is highly plastic owing to capsular adrenocortical stem cells (ACSC) that are highly sensitive to their cognate growth factor: adrenocorticotrophic hormone (ACTH). During autoimmune Addison?s disease (adrenocortical failure) the steroidogenic cells of the adrenal cortex are attacked and destroyed by the immune system, with the steroidogenic enzymes as the targets of immune attack. Because the ACSC progenitors do not express the steroidogenic enzymes that are the markers of terminal differentiation of adrenocortical cells, it is probable that they are spared from destruction in autoimmune Addison?s disease and become quiescent following exogenous suppression of their ACTH driver. This study will use a staged regimen of administered recombinant ACTH (?synacthen?) to re-activate dormant endogenous ACSCs and regenerate functional steroidogenesis in 12 patients with autoimmune Addison?s disease. The first 10 week phase of the study will use once daily ACTH injections. The second phase will use a subcutaneous ACTH infusion, either infused at a constant rate over 24 hours or as a 12hr pulsatile infusion to stimulate ACSC proliferation, differentiation and steroidogenesis. Response to therapy will be judged by conventional endocrine markers of adrenal function. This pragmatic study will provide valuable proof of principle that ACSCs remain viable and ACTH responsive, even in established adrenal failure. In addition, this investigation has the potential to launch a new field of regenerative adrenal therapies, with potential benefit for up to 8,500 individuals in the UK with autoimmune adrenocortical failure, a chronic and morbid condition.</gtr:technicalSummary><gtr:fund><gtr:end>2012-08-03</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-08-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>287337</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Faculty of Health and Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Reproductive and Vascular Biology Group</gtr:department><gtr:description>MCRs in uterus</gtr:description><gtr:id>30B516FC-4651-4685-BC1B-A12D38A269E7</gtr:id><gtr:impact>A journal paper was published during 2014.</gtr:impact><gtr:partnerContribution>We co-supervised a MRes student in performing IHC studies for MCR expression in Uterus. A paper is being written about the findings.</gtr:partnerContribution><gtr:piContribution>A side effect of the ACTH therapy was menstrual disturbance and the mechanism for this wasn't known. We made a collaboration with a reproductive biology researcher (Dr. G. Lash, Newcastle Uni) to explore melanocortin receptor expression in uterus.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Endocrinology, Diabetes and Metabolism</gtr:department><gtr:description>Steroid Metabolome</gtr:description><gtr:id>5D7EB5E5-F008-44E7-8E72-37A9ECC6DC6F</gtr:id><gtr:impact>Research paper in JCEM</gtr:impact><gtr:partnerContribution>Provided GC-MS/MS of urine steroid metabolome</gtr:partnerContribution><gtr:piContribution>Provided samples for analysis, and IP for the concept being examined</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>28000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept (Newcastle University managed, MRC)</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Newcastle University</gtr:fundingOrg><gtr:id>4C4E8BBC-28CC-4797-A464-40606BCC9164</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>530000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Clinical Studies</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J002526/1</gtr:fundingRef><gtr:id>B3721ACA-8B26-4F66-8D8F-0B49B8B4965A</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We have discovered that Addison's disease is heterogeneous in terms of residual steroidogenic function and that some patients retain recoverable adrenal function for up to 8 yrs after diagnosis</gtr:description><gtr:id>11653DD3-63AE-427A-86A7-649C28CE8C5E</gtr:id><gtr:impact>This forms the basis of a grant application currently in review (MRC DCS scheme) and the likely basis of a second programme grant application to take the initial observations further.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Residual adrenal plasticity</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EU Adrenal insufficiency guidelines</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>39D1029E-E792-4C12-A59C-6786EBCA6EF2</gtr:id><gtr:impact>Standardised investiagtion and management of a rare condition across the EU.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>We demonstrated that in 2 of 13 patients with established Addison's diease, that adrenal regeneration can recur during high dose ACTH stimulation. This led to remission in these 2 patients and one remains 'cured' for the last 30 months.</gtr:description><gtr:id>1453E593-F035-4147-B983-7FC0BDC5EF67</gtr:id><gtr:impact>The therapy has been life-changing for one patient so far. The key concept, that there is residual adrenal function in 20-30% of Addison's patients is the real IP. The paper is just published PMID: 24170102.</gtr:impact><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>RoSA: revival of stem cells in Addison's disease</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>NCT 01371526</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E2F035D7-1C16-4758-A871-9D4D16760B47"><gtr:id>E2F035D7-1C16-4758-A871-9D4D16760B47</gtr:id><gtr:title>Spontaneous and tetracosactide-induced anti-ACTH antibodies in man.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/035d0e4c4756ccd97aba54ac23cbeebc"><gtr:id>035d0e4c4756ccd97aba54ac23cbeebc</gtr:id><gtr:otherNames>Gan EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1CA149DC-A7D2-4044-AF17-5020A20D315C"><gtr:id>1CA149DC-A7D2-4044-AF17-5020A20D315C</gtr:id><gtr:title>Current and emerging therapies for Addison's disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in endocrinology, diabetes, and obesity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a638e19d45cc5ab3047e7a8e39f2e9c4"><gtr:id>a638e19d45cc5ab3047e7a8e39f2e9c4</gtr:id><gtr:otherNames>Napier C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1752-296X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7FD403F6-64D2-4D3B-AEA4-AEA6021323FC"><gtr:id>7FD403F6-64D2-4D3B-AEA4-AEA6021323FC</gtr:id><gtr:title>Residual adrenal function in autoimmune Addison's disease: improvement after tetracosactide (ACTH1-24) treatment.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/035d0e4c4756ccd97aba54ac23cbeebc"><gtr:id>035d0e4c4756ccd97aba54ac23cbeebc</gtr:id><gtr:otherNames>Gan EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DD0BAD01-4F4D-4D31-B79C-A2CE0E76D738"><gtr:id>DD0BAD01-4F4D-4D31-B79C-A2CE0E76D738</gtr:id><gtr:title>Saving lives of in-patients with adrenal insufficiency: implementation of an alert scheme within the Newcastle-upon-Tyne Hospitals e-Prescribing platform.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/40d4aefc449834f9c0aba834ea778607"><gtr:id>40d4aefc449834f9c0aba834ea778607</gtr:id><gtr:otherNames>Mitchell AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/11227E0C-6E0C-46A3-AE2A-FBEE0EFBF619"><gtr:id>11227E0C-6E0C-46A3-AE2A-FBEE0EFBF619</gtr:id><gtr:title>MANAGEMENT OF ENDOCRINE DISEASE: Regenerative therapies in autoimmune Addison's disease.</gtr:title><gtr:parentPublicationTitle>European journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/035d0e4c4756ccd97aba54ac23cbeebc"><gtr:id>035d0e4c4756ccd97aba54ac23cbeebc</gtr:id><gtr:otherNames>Gan EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0804-4643</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DFE62FC4-8DF5-473E-A095-73803F7EE313"><gtr:id>DFE62FC4-8DF5-473E-A095-73803F7EE313</gtr:id><gtr:title>Linkage Analysis in Autoimmune Addison's Disease: NFATC1 as a Potential Novel Susceptibility Locus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/40d4aefc449834f9c0aba834ea778607"><gtr:id>40d4aefc449834f9c0aba834ea778607</gtr:id><gtr:otherNames>Mitchell AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/50B6B0FB-C62F-4C12-A5EE-9134547A2D4F"><gtr:id>50B6B0FB-C62F-4C12-A5EE-9134547A2D4F</gtr:id><gtr:title>Insufficient evidence to favour prednisolone over hydrocortisone in glucocorticoid replacement.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f78ce76102cae0546d0d6557520cfc67"><gtr:id>f78ce76102cae0546d0d6557520cfc67</gtr:id><gtr:otherNames>Pearce SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/73221E11-574A-40AB-BE41-E26182FBCA49"><gtr:id>73221E11-574A-40AB-BE41-E26182FBCA49</gtr:id><gtr:title>Impact of Month of Birth on the Risk of Development of Autoimmune Addison's Disease.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b865d2d8238576275b62c4feb90ac66"><gtr:id>9b865d2d8238576275b62c4feb90ac66</gtr:id><gtr:otherNames>Pazderska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4206E52A-138A-4C35-A9B3-309B9BAB8EF4"><gtr:id>4206E52A-138A-4C35-A9B3-309B9BAB8EF4</gtr:id><gtr:title>Autoimmune Addison disease: pathophysiology and genetic complexity.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/40d4aefc449834f9c0aba834ea778607"><gtr:id>40d4aefc449834f9c0aba834ea778607</gtr:id><gtr:otherNames>Mitchell AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1759-5029</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/012AC612-36B8-40D9-844A-44EF68196E81"><gtr:id>012AC612-36B8-40D9-844A-44EF68196E81</gtr:id><gtr:title>CTLA-4 as a genetic determinant in autoimmune Addison's disease.</gtr:title><gtr:parentPublicationTitle>Genes and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9d8f9b1266e842b448d31a804555e684"><gtr:id>9d8f9b1266e842b448d31a804555e684</gtr:id><gtr:otherNames>Wolff AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1466-4879</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F0EFD414-F28E-44C4-BA86-AF6E703EE309"><gtr:id>F0EFD414-F28E-44C4-BA86-AF6E703EE309</gtr:id><gtr:title>Loperamide-induced hypopituitarism.</gtr:title><gtr:parentPublicationTitle>BMJ case reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a638e19d45cc5ab3047e7a8e39f2e9c4"><gtr:id>a638e19d45cc5ab3047e7a8e39f2e9c4</gtr:id><gtr:otherNames>Napier C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1757-790X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9938490C-6DDA-47A1-A4AC-8032E1CA49F2"><gtr:id>9938490C-6DDA-47A1-A4AC-8032E1CA49F2</gtr:id><gtr:title>Expression of melanocortin receptors in human endometrium.</gtr:title><gtr:parentPublicationTitle>Human reproduction (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e51ed23671af5fe367b55b9fd4204c13"><gtr:id>e51ed23671af5fe367b55b9fd4204c13</gtr:id><gtr:otherNames>Lantang AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0268-1161</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EF81F3D0-3D78-4A15-9746-0E353706E3D3"><gtr:id>EF81F3D0-3D78-4A15-9746-0E353706E3D3</gtr:id><gtr:title>Residual adrenal function in autoimmune Addison's disease: improvement after tetracosactide (ACTH1-24) treatment.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/035d0e4c4756ccd97aba54ac23cbeebc"><gtr:id>035d0e4c4756ccd97aba54ac23cbeebc</gtr:id><gtr:otherNames>Gan EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/73F15C2B-DFC3-4A47-BF4F-53544A96B74D"><gtr:id>73F15C2B-DFC3-4A47-BF4F-53544A96B74D</gtr:id><gtr:title>AIRE is not essential for the induction of human tolerogenic dendritic cells.</gtr:title><gtr:parentPublicationTitle>Autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44ffcf7282a73f1ed1a7a4f75f626ba1"><gtr:id>44ffcf7282a73f1ed1a7a4f75f626ba1</gtr:id><gtr:otherNames>Crossland KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0891-6934</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7C70B2C-47E4-4E86-91EC-F2E5DDCEF46D"><gtr:id>B7C70B2C-47E4-4E86-91EC-F2E5DDCEF46D</gtr:id><gtr:title>A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b865d2d8238576275b62c4feb90ac66"><gtr:id>9b865d2d8238576275b62c4feb90ac66</gtr:id><gtr:otherNames>Pazderska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900001</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>